We are pleased to invite investors and analysts to participate in our virtual event on Monday, 30 October 2023, highlighting Roche’s Neuroscience portfolio, including the latest data presented at ECTRIMS 2023 (Ocrevus, fenebrutinib) and CTAD 2023 (trontinemab, gamma-secretase modulator).   17:00 – 18:15 CET / 16:00 - 17:15 GMT 12:00 – 1:15 pm EDT / 9:00 – 10:15 am PDT   The webinar will start with presentations, followed by a Q&A session (live access to the speakers). The slides will be available for download at 16:00 CET on the day of the event. > click here   Access to virtual event (pre-registration required) Please pre-register for our webinar here*.   Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.   A replay of the webcast will be available via > ir.roche.com   *privacy notice   Best regards,
Bruno Eschli Head of Investor Relations

 

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com	Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

 

get the latest news and updates to your inbox.